TONIX PHARMACEUTICALS, INC.

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2017–2025

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2025	—	4	1
2024	—	4	1
2023	—	4	1
2022	—	4	1
2021	—	4	1
2020	—	4	1
2019	—	4	1
2018	—	4	1
2017	—	2	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
CARDINAL POINT PARTNERS	—	34

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
SENATE	28
HOUSE OF REPRESENTATIVES	27
Health & Human Services, Dept of (HHS)	6
Defense, Dept of (DOD)	4
Army, Dept of (Other)	1
Veterans Affairs, Dept of (VA)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Defense	Defense	19
Disaster Planning/Emergencies	Disaster Planning/Emergencies	14
Budget/Appropriations	Budget/Appropriations	14
Veterans	Veterans	8
Health Issues	Health Issues	4

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 8774118th Congress

Department of Defense Appropriations Act, 2025

2024 · fourth_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774, S. 4921) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (H.R. 9029, S. 4942)

Client expense: — · Firm income: $30,000

Matched citations: H.R. 8774

H.R. 9029118th Congress

Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025

2024 · fourth_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774, S. 4921) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (H.R. 9029, S. 4942)

Client expense: — · Firm income: $30,000

Matched citations: H.R. 9029

S. 2333118th Congress

Pandemic and All-Hazards Preparedness and Response Act

2024 · fourth_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Medical Countermeasures research, development and acquisition in the Pandemic All-Hazards Preparedness and Response Act (S. 2333).

Client expense: — · Firm income: $30,000

Matched citations: S. 2333

S. 4921118th Congress

Department of Defense Appropriations Act, 2025

2024 · fourth_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774, S. 4921) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (H.R. 9029, S. 4942)

Client expense: — · Firm income: $30,000

Matched citations: S. 4921

Show 21 more cited filings

S. 4942118th Congress

Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025

2024 · fourth_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774, S. 4921) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (H.R. 9029, S. 4942)

Client expense: — · Firm income: $30,000

Matched citations: S. 4942

H.R. 8070118th Congress

Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025

2024 · third_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Biodefense research in the National Defense Authorization Act for FY2025 (H.R. 8070 and S. 4638)

Client expense: — · Firm income: $30,000

Matched citations: H.R. 8070

H.R. 8774118th Congress

Department of Defense Appropriations Act, 2025

2024 · third_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774, S. 4921) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (H.R. 9029, S. 4942)

Client expense: — · Firm income: $30,000

Matched citations: H.R. 8774

H.R. 9029118th Congress

Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025

2024 · third_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774, S. 4921) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (H.R. 9029, S. 4942)

Client expense: — · Firm income: $30,000

Matched citations: H.R. 9029

S. 2333118th Congress

Pandemic and All-Hazards Preparedness and Response Act

2024 · third_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Medical Countermeasures research, development and acquisition in the Pandemic All-Hazards Preparedness and Response Act (S. 2333).

Client expense: — · Firm income: $30,000

Matched citations: S. 2333

S. 4638118th Congress

National Defense Authorization Act for Fiscal Year 2025

2024 · third_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Biodefense research in the National Defense Authorization Act for FY2025 (H.R. 8070 and S. 4638)

Client expense: — · Firm income: $30,000

Matched citations: S. 4638

S. 4921118th Congress

Department of Defense Appropriations Act, 2025

2024 · third_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774, S. 4921) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (H.R. 9029, S. 4942)

Client expense: — · Firm income: $30,000

Matched citations: S. 4921

S. 4942118th Congress

Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025

2024 · third_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774, S. 4921) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (H.R. 9029, S. 4942)

Client expense: — · Firm income: $30,000

Matched citations: S. 4942

H.R. 8070118th Congress

Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025

2024 · second_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Biodefense research in the National Defense Authorization Act for FY2025 (H.R. 8070 and S. 4638)

Client expense: — · Firm income: $30,000

Matched citations: H.R. 8070

H.R. 8774118th Congress

Department of Defense Appropriations Act, 2025

2024 · second_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 (No bill numbers) National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (No bill numbers)

Client expense: — · Firm income: $30,000

Matched citations: H.R. 8774

S. 2333118th Congress

Pandemic and All-Hazards Preparedness and Response Act

2024 · second_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Medical Countermeasures research, development and acquisition in the Pandemic All-Hazards Preparedness and Response Act (S. 2333).

Client expense: — · Firm income: $30,000

Matched citations: S. 2333

S. 4638118th Congress

National Defense Authorization Act for Fiscal Year 2025

2024 · second_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Biodefense research in the National Defense Authorization Act for FY2025 (H.R. 8070 and S. 4638)

Client expense: — · Firm income: $30,000

Matched citations: S. 4638

H.R. 4365118th Congress

Department of Defense Appropriations Act, 2024

2023 · fourth_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2024 (H.R. 4365, S. 2587)

Client expense: — · Firm income: $30,000

Matched citations: H.R. 4365

S. 2587118th Congress

Department of Defense Appropriations Act, 2024

2023 · fourth_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2024 (H.R. 4365, S. 2587)

Client expense: — · Firm income: $30,000

Matched citations: S. 2587

H.R. 4365118th Congress

Department of Defense Appropriations Act, 2024

2023 · third_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2024 (H.R. 4365, S. 2587)

Client expense: — · Firm income: $30,000

Matched citations: H.R. 4365

S. 2587118th Congress

Department of Defense Appropriations Act, 2024

2023 · third_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2024 (H.R. 4365, S. 2587)

Client expense: — · Firm income: $30,000

Matched citations: S. 2587

H.R. 4365118th Congress

Department of Defense Appropriations Act, 2024

2023 · second_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2024 (H.R. 4365)

Client expense: — · Firm income: $30,000

Matched citations: H.R. 4365

H.R. 2617117th Congress

Consolidated Appropriations Act, 2023

2022 · fourth_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Proposed legislation on research and development into medical countermeasures for pandemic response and biosecurity in the PREVENT Pandemics Act S.3799 and the FY2023 Consolidated Appropriations Act (H.R. 2617).

Client expense: — · Firm income: $30,000

Matched citations: H.R. 2617

H.R. 2617117th Congress

Consolidated Appropriations Act, 2023

2022 · fourth_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Advocating for expanded funding for advanced development of COVID vaccines in the Labor-HHS-Education Appropriations Act for FY 2023 (H.R. 8295) and the Consolidated Appropriations Act, FY2023 (H.R. 2617). Advocating for expanded funding for Defense Department research and development on biodefense vaccines in the Defense Appropriations Act for FY 2023 (H.R. 8236) and the Consolidated Appropriations Act, FY2023 (H.R. 2617).

Client expense: — · Firm income: $30,000

Matched citations: H.R. 2617

H.R. 7776117th Congress

James M. Inhofe National Defense Authorization Act for Fiscal Year 2023

2022 · fourth_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Advocating for increased funding for research and development on biodefense vaccines in the National Defense Authorization Act for FY2023 (H.R. 7900, S. 4543, H.R. 7776)

Client expense: — · Firm income: $30,000

Matched citations: H.R. 7776

H.R. 7900117th Congress

National Defense Authorization Act for Fiscal Year 2023

2022 · fourth_quarter · Firm: CARDINAL POINT PARTNERS

Open original LDA filing ↗

Cited source text and reported amounts

Advocating for increased funding for research and development on biodefense vaccines in the National Defense Authorization Act for FY2023 (H.R. 7900, S. 4543, H.R. 7776)

Client expense: — · Firm income: $30,000

Matched citations: H.R. 7900

Source: Senate LDA

TONIX PHARMACEUTICALS, INC. — Lobbying Disclosure | Poliscope